Instructions for Liv.52 tablets No. 100
Composition
active ingredients: 1 tablet contains powders: caper roots (Capparis spinosa) – 65 mg; wild chicory seeds (Cichorium intybus) – 65 mg; black nightshade (Solanum nigrum) – 32 mg; western cassia (Cassia occidentalis) – 16 mg; terminalia arjuna bark (Terminalia arjuna) – 32 mg; tamarisk (Tamarix gallica) – 16 mg; yarrow seeds (Achillea millefolium) – 16 mg; iron oxide (Mandur bhasma) – 33 mg; which are treated with an aqueous extract of: white eclipta (Eclipta alba), bitter phyllantus (Phyllanthus amarus), Boerhaavia diffusa roots (Boerhaavia diffusa), Tinospora cordifolia stems (Tinospora cordifolia), radish roots (Raphanus sativus), Emblica officinalis fruits (Emblica officinalis), Plumbago rhizome (Plumbago zeylanica), Embelia ribes seeds (Embelia ribes), Terminalia chebula fruits (Terminalia chebula), and Fumaria officinalis;
excipients: magnesium stearate, microcrystalline cellulose, croscarmellose sodium, sodium carboxymethylcellulose, colloidal anhydrous silicon dioxide.
Dosage form
Pills.
Main physicochemical properties: round, biconvex tablets of greenish-gray color with light and dark inclusions.
Pharmacotherapeutic group
Drugs used for liver and biliary tract diseases.
ATX code A05.
Pharmacological properties
Pharmacodynamics
Combined herbal hepatoprotective agent. Protects the liver parenchyma from the effects of toxic agents. The hepatoprotective effect of the drug is due to the antioxidant and membrane-stabilizing properties of the components included in its composition. The drug increases the level of endogenous tocopherols in hepatocytes and the level of cytochrome P450. Liv.52 stimulates the biosynthesis of proteins and phospholipids. Promotes the restoration of hepatocytes, reduces degenerative, fatty and fibrous changes, enhances intracellular metabolism.
The drug regulates the level of blood plasma proteins, normalizes the albumin/globulin ratio. Provides normalization of plasma transaminases, cholesterol, triglycerides, reducing the manifestations of dyslipidemia. Reduces bilirubin and alkaline phosphatase. Increases the liver's ability to deposit glycogen.
Improves the colloidal properties of bile, prevents the formation of gallstones. Improves the contractile function of the gallbladder. Improves the processes of digestion and absorption of food. Stimulates hematopoiesis.
In alcoholic liver damage, the drug reduces the level of ethanol in the blood and urine; increases the activity of acetaldehyde dehydrogenase, which helps reduce the level of acetaldehyde; prevents the binding of acetaldehyde to cell proteins, accelerating its excretion.
Indication
Comprehensive treatment and prevention of chronic diffuse liver diseases, alcoholic liver damage, radioactive and chemotherapeutic liver damage. As a means to increase the body's resistance to hepatotoxic lesions, to accelerate recovery during the period of convalescence after serious illnesses, surgeries. Cholecystoangiocholitis and biliary dyskinesia.
Contraindication
Hypersensitivity to the components of the drug and to other plants of the Asteraceae family. Gallstone disease. Acute inflammatory diseases of the stomach and intestines. Increased blood clotting, tendency to thrombosis.
Interaction with other medicinal products and other types of interactions
When Liv.52 is used simultaneously with ibuprofen, the level of the latter in the body decreases due to delayed absorption. When used simultaneously with tetracycline or doxycycline, the bioavailability of antibiotics decreases.
Application features
There are reports of the development of epidermal necrolysis in patients with chronic and acute infectious hepatitis who took Liv.52.
In acute infectious hepatitis, the drug is used as prescribed by a doctor with caution.
Ability to influence reaction speed when driving vehicles or other mechanisms
No effect.
Use during pregnancy or breastfeeding
Contraindicated.
Method of administration and doses
Liv.52 tablets are taken orally.
Adults and children over 14 years of age are prescribed 2 tablets 3 times a day.
Children aged 6 to 14 years are prescribed 1 tablet 3 times a day.
The course of treatment is determined by the doctor depending on the nature and course of the disease.
For alcoholic liver damage, adults are prescribed 2 tablets 3 times a day for 1 month, then 1 tablet 3 times a day for 6–12 months.
Children
The effectiveness and safety of the drug in children under 6 years of age have not been established, therefore it is contraindicated for use in this age group of patients.
Overdose
No cases of overdose have been observed. Dizziness or increased manifestations of adverse reactions are possible. There is no specific antidote. Treatment is symptomatic.
Adverse reactions
Skin and subcutaneous tissue disorders: hyperemia, rash, itching, skin edema, severe skin reactions, including toxic epidermal necrolysis.
Hypersensitivity reactions are possible when using the drug.
Expiration date
3 years.
Storage conditions
Store at a temperature not exceeding 30 °C in the original packaging.
Keep out of reach of children.
Packaging
100 tablets in a plastic jar, 1 jar in a cardboard box.
Vacation category
Without a prescription.
Producer
Himalaya Drag Company.
Location of the manufacturer and its business address
Makali, Bangalore – 562 162, India.
